Search research articles
Contact Us
Filters
Showing results (491-500 of 510) with videos related to
Page
of 51
Sort By:
Journal of Medicinal Chemistry
|
July 14, 2022
Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction
John M Ketcham, Jacob Haling, Shilpi Khare, et al.
The New England Journal of Medicine
|
September 30, 2014
Crizotinib in ROS1-rearranged non-small-cell lung cancer
Alice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, et al.
Cancer Research
|
July 22, 2025
Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer
Kristina Drizyte-Miller, Lars D Engstrom, Jeffrey A Klomp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2017
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring <i>MET</i> Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models
Lars D Engstrom, Ruth Aranda, Matthew Lee, et al.
Journal of Medicinal Chemistry
|
December 10, 2021
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS<sup>G12D</sup> Inhibitor
Xiaolun Wang, Shelley Allen, James F Blake, et al.
Nature Medicine
|
October 10, 2022
Anti-tumor efficacy of a potent and selective non-covalent KRAS<sup>G12D</sup> inhibitor
Jill Hallin, Vickie Bowcut, Andrew Calinisan, et al.
Journal of Medicinal Chemistry
|
March 13, 2024
Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein
John M Ketcham, Stephen J Harwood, Ruth Aranda, et al.
ACS Medicinal Chemistry Letters
|
January 8, 2019
Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity
Jay B Fell, John P Fischer, Brian R Baer, et al.
Molecular Cancer Therapeutics
|
June 21, 2024
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Niranjan Sudhakar, Larry Yan, Fadia Qiryaqos, et al.
Cancer Discovery
|
August 8, 2023
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer
Lars D Engstrom, Ruth Aranda, Laura Waters, et al.
Page
of 51
Search research articles
Search
Showing results (491-500 of 510) with videos related to
Sort By:
Page
of 51
Journal of Medicinal Chemistry
|
July 14, 2022
Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction
John M Ketcham, Jacob Haling, Shilpi Khare, et al.
The New England Journal of Medicine
|
September 30, 2014
Crizotinib in ROS1-rearranged non-small-cell lung cancer
Alice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, et al.
Cancer Research
|
July 22, 2025
Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer
Kristina Drizyte-Miller, Lars D Engstrom, Jeffrey A Klomp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2017
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring <i>MET</i> Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models
Lars D Engstrom, Ruth Aranda, Matthew Lee, et al.
Journal of Medicinal Chemistry
|
December 10, 2021
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS<sup>G12D</sup> Inhibitor
Xiaolun Wang, Shelley Allen, James F Blake, et al.
Nature Medicine
|
October 10, 2022
Anti-tumor efficacy of a potent and selective non-covalent KRAS<sup>G12D</sup> inhibitor
Jill Hallin, Vickie Bowcut, Andrew Calinisan, et al.
Journal of Medicinal Chemistry
|
March 13, 2024
Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein
John M Ketcham, Stephen J Harwood, Ruth Aranda, et al.
ACS Medicinal Chemistry Letters
|
January 8, 2019
Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity
Jay B Fell, John P Fischer, Brian R Baer, et al.
Molecular Cancer Therapeutics
|
June 21, 2024
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Niranjan Sudhakar, Larry Yan, Fadia Qiryaqos, et al.
Cancer Discovery
|
August 8, 2023
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer
Lars D Engstrom, Ruth Aranda, Laura Waters, et al.
Page
of 51